Baxter International (BAX) to Release Earnings on Friday

Baxter International (NYSE:BAX - Get Free Report) is scheduled to announce its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of $0.78 per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.02. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.75 billion. During the same period last year, the business posted $0.55 earnings per share. Baxter International's revenue was up 2.8% on a year-over-year basis. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Stock Performance

NYSE BAX traded up $0.17 during trading hours on Friday, reaching $35.87. 3,117,355 shares of the company were exchanged, compared to its average volume of 4,043,347. The stock has a market capitalization of $18.30 billion, a P/E ratio of 7.43, a P/E/G ratio of 1.21 and a beta of 0.59. The company has a quick ratio of 0.91, a current ratio of 1.40 and a debt-to-equity ratio of 1.35. Baxter International has a 1 year low of $32.28 and a 1 year high of $44.01. The business's 50 day simple moving average is $37.64 and its 200-day simple moving average is $36.29.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on BAX shares. StockNews.com raised shares of Baxter International from a "hold" rating to a "buy" rating in a research report on Tuesday, October 22nd. The Goldman Sachs Group upped their price target on shares of Baxter International from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Thursday, August 8th. Morgan Stanley cut shares of Baxter International from an "equal weight" rating to an "underweight" rating and dropped their price target for the company from $39.00 to $30.00 in a research note on Monday, July 15th. JPMorgan Chase & Co. dropped their price target on shares of Baxter International from $44.00 to $42.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 7th. Finally, Citigroup upped their price target on shares of Baxter International from $38.00 to $40.00 and gave the company a "neutral" rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $41.20.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.